Background: Atomised intranasal dexmedetomidine administration is an attractive option when sedation is required for paediatric diagnostic procedures, as vascular access is not required. The risk of haemodynamic instability caused by dexmedetomidine necessitates better understanding of its pharmacokinetics in young children. To date, intranasal dexmedetomidine pharmacokinetics has only been studied in adults.
Editor's key points
Dexmedetomidine is a highly selective a2 adrenergic agonist with anxiolytic, sedative, and mild analgesic properties. Although intranasal use is well-described in children, little is known of its pharmacokinetics in this setting. The pharmacokinetics of intranasal and i.v. dexmedetomidine was studied in 18 children. After intranasal administration, peak plasma concentrations occurred at 46 min, and bioavailability was >80%.
Intranasal dexmedetomidine is an attractive needle-free sedative for paediatric use where i.v. access is unnecessary or may be deferred until sedation is achieved. Dexmedetomidine has been widely used for paediatric sedation for nonpainful procedures. 1 It has a short half-life, promotes a calm emergence, and is associated with maintenance of airway stability and spontaneous ventilation. 2e4 Dexmedetomidine is effective and painless when administered by the nasal route. 5 Pharmacodynamic studies of intranasal dexmedetomidine onset, efficacy, and adverse effects have been reported in children.
6e10
To minimise side effects and instruct clinical dosing, it is imperative to gather pharmacokinetic information on dexmedetomidine in paediatric patients. The pharmacokinetics of i.v. dexmedetomidine have been studied in children, including premature infants. 11e13 However, while one pharmacokinetic study of intranasal bolus dosing of dexmedetomidine has been performed in adult humans, 14 no such data exist in children.
This represents a substantial lack of information, as rapid administration of dexmedetomidine is associated with hemodynamic alterations, such as bradycardia, arterial hypotension, and hypertension. 15 The margin of safety with intranasal dosing is currently unknown. Accordingly, this represents the first pharmacokinetic study of atomised intranasal dexmedetomidine in children. Cardiac surgery patients were selected for this study because of the availability of intra-arterial access for repeated blood sampling, routine use of dexmedetomidine as part of our anaesthetic plan, and our previously published pharmacodynamic data with intranasal dexmedetomidine in a similar patient population. 7, 10 The aim of the study was to characterise the peak drug concentration in plasma for two different doses of intranasal dexmedetomidine and to determine bioavailability compared with i.v. dosing. Based on prior adult pharmacokinetic and paediatric pharmacodynamic data, we hypothesised that intranasal atomised dexmedetomidine would reach plasma concentrations associated with sedation in approximately 20 min, with peak plasma concentrations within 60 min of administration.
7,14

Methods
This prospective pharmacokinetic study in a single quaternary paediatric referral centre was registered at clinicaltrials.gov on January 8, 2016 
Study population
The enrolment period was from January 2016 to December 2016. Paediatric patients for elective cardiac surgery aged 6e48 months were eligible for this study. All patients were scheduled to receive postoperative sedation with i.v. dexmedetomidine infusions. Written, informed consent was obtained from a parent or legal guardian. Eighteen children were sequentially assigned to three treatment groups, each containing six children. With no prior available paediatric data and given funding constraints, we chose six patients per group and eight to nine bioassay samples per patient. Terminal elimination was not studied because of the confounding effects of hemodilution with initiation of cardiopulmonary bypass (CPB) within 2 h of drug administration. Exclusion criteria were: patients admitted to the hospital before surgery, patients with a history of cardiac conduction system disease (e.g. sinus node disease, first or second degree atrioventricular block) or formally diagnosed channelopathy (e.g. "long QT syndrome"), current treatment with digoxin, alpha-adrenergic or beta-adrenergic agonists or antagonists, clonidine, anti-arrhythmic medications, anticonvulsants, presence of life-threatening medical conditions (ASA Physical Status 4 or 5), previous exposure to dexmedetomidine within 1 week, or unrepaired coarctation of the aorta. Patients with acute nasal or respiratory symptoms on the day of the study were excluded because of potential interference with intranasal absorption.
Clinical protocol
All subjects received an inhalation induction of anaesthesia with sevoflurane followed by i.v. and intra-arterial cannula placement and tracheal intubation. Medications administered before surgery and during the study period were recorded. Standard monitoring per ASA guidelines was fully instituted before dexmedetomidine administration. Patients were in the supine position with their head positioned in the midline. The first six patients received undiluted intranasal dexmedetomidine (Mylan Pharmaceuticals, Canonsburg, PA, USA; 100 mg ml À1 ), 1 mg kg À1 , by atomiser (Teleflex MAD Nasal; Research Triangle Park, NC, USA) in one naris as a rapid spray from a 1 ml syringe containing the dexmedetomidine and 0.2 ml air as a 'chaser' to ensure complete expulsion of the medication. 17 The second six patients received 2 mg kg À1 intranasal dexmedetomidine in one naris in identical fashion. The maximum volume administered was 0.29 ml. The syringe was oriented approximately 30 degrees from horizontal in supine patients to direct the atomised medication cephalad toward the upper third of the nasal cavity. 18 All nasal dexmedetomidine administration was performed by a single physician (J.W.M.) with extensive experience using the atomiser. To determine bioavailability, the final six patients received 1 mg kg
dexmedetomidine (Mylan Pharmaceuticals; 4 mg ml À1 ) over 10 min by infusion pump into a peripheral i.v. cannula. Supplemental anaesthetic drugs were reduced by the anaesthesia team in anticipation of the co-anaesthetic effects of the administered dexmedetomidine. The patients each received less than 10 ml kg À1 i.v. fluid before CPB by commonly agreed practice in our institution. A case review for potential adverse events related to dexmedetomidine was completed for each group before the increase in dose.
Plasma sample collection and bioassay
Arterial blood samples (1 mL) were obtained before administration of dexmedetomidine ('baseline') and then at 10 min intervals after administration for the first hour. The 10-min sample in the i.v. dexmedetomidine group was obtained as soon as the 1 mg kg À1 bolus was completed. If CPB was not initiated by 120 min after dexmedetomidine administration, then a 120-min sample was collected. A final arterial sample was obtained 2 min after administration of 400 units kg À1 of heparin for CPB, a time point that varied among study participants. Blood samples were centrifuged, and plasma was separated and stored in a polyethylene tube at À70 C until bioassay. Need for atropine, glycopyrrolate, epinephrine, ephedrine, or electrical pacing before cannulation for CPB were documented as potential adverse events. Arterial plasma dexmedetomidine was quantified by a validated isotope-dilution 2D high-performance liquid chromatography/tandem mass spectrometry (LC/LC-MS/MS) assay by iC42 Clinical Research and Development (University of Colorado Denver, Aurora, CO, USA). Plasma specimens were analysed by liquid chromatography tandem mass spectrometry (LC-MS/MS). Briefly, 100 ml of plasma was transferred into a 1.5 ml vial and 600 ml of 0. , ion spray voltage 5500 V, source temperature 500 C, and ion source gas 240 litre min
À1
. MS/MS settings were declustering potential 80 V, exit potential 10 V, collision energy 25 eV, and cell exit potential 16 V. Quantification was based on plotting the dexmedetomidine/internal standard area-under-the-peak ratios and external calibration curves (linear fit, 1/X weighting) using the Analyst software (version 1.6.2., Sciex, Framingham, Massachusetts, USA). Lower limit of quantifications was 20 pg ml À1 and linear range was 20e1000 pg ml À1 (r 2 >0.99) for dexmedetomidine. The four concentrations of the quality control samples were 64, 240, 600, and 800 pg ml À1 . The extraction efficiency (recovery) ranged from 79.9% to 101.2% and was determined at the concentrations of the quality control samples following the recommendations by Matuszewski and colleagues. 19 The imprecision was (coefficient of variance) 4.6e12.9%. No significant matrix effects or carry-over was detected.
Pharmacokinetic analysis
Pharmacokinetic analysis was performed using descriptive non-compartmental analysis with WinNonlin (version 7.0, Certara, Princeton, NJ, USA) and the concentration-time plots for individual patient, maximum plasma concentration (C max ), and time at which C max was observed T max estimates were derived. To compare our findings with literature reports, graphical coordinates of published plots were obtained by DIGIT software (version 1.0.4, Simulation Plus Inc., Lancaster, CA, USA) and a summary graph depicting published results along with our observations was developed using GraphPad software (GraphPad Prism version 7.02, La Jolla, CA, USA).
The population pharmacokinetic modelling of data was performed by non-linear mixed effect modelling with NON-MEM software (version 7.2, ICON, Ellicot City, MD, USA). One and two compartment models were tested to describe the dexmedetomidine plasma concentration-time profile, during model development. The first order conditional estimation method with interaction was used for all runs. A combined additive and proportional error model was used to estimate the residual error. The best model was selected using goodness of fit diagnostic plots, objective function value (OFV) and evaluation of population fixed effect and random parameters. To account for the influence of variation in body size on PK, PK parameters were allometrically scaled with body weight using a power coefficient of 0.75 for clearance (CL) and 1.0 for volume of distribution (V), as shown in the following equation:
where BW i represents the body weight of individual (i) and 70 kg is a standard adult body weight. An intranasal absorption model was developed to obtain estimates of bioavailability (F). Dexmedetomidine intranasal administration and i.v. administration data were obtained from different patients. The sampling times were similar for the i.v. and intranasal groups. Simultaneous analysis of intranasal and i.v. administration data was performed to obtain population PK parameter estimates for CL, V, and bioavailability. A first order absorption rate constant (Ka) and lag time (ALAG) were included and fixed in the PK model to describe dexmedetomidine absorption. Different values for Ka and ALAG for first order absorption with lag time for intranasal dexmedetomidine administration were tried and best fit was obtained by fixing Ka and ALAG at 0.0157 min À1 and 5.00 min, respectively.
Model evaluation
The goodness of fit diagnostic plots, OFV and Akaike information criterion (AIC) were used for model evaluation. 
Results
During the period from January 21, 2016 to December 16, 2016, 18 children were studied. Ninety-four patients were screened for eligibility and 24 patients met inclusion criteria when adequate research staff were available. The rate of consent to participate in this study was 88% (21 patients). Once enrolled, there were three dropouts because of a preoperative change in medical status observed before anaesthetic induction. Subject characteristics are presented in Table 1 . The average age was 25.6 months (range 6e44 months). The study population included eight males and 10 females, two selfidentified as AfricaneAmerican and 16 as Caucasian, three prematurely born children (estimated gestational age less than 37 weeks), and four cyanotic subjects with baseline awake oxygen saturation less than 92%. Three subjects were taking enalapril (held on the day of surgery), one was taking aspirin, one was taking furosemide, and one was taking levothyroxine. No patient had a diagnosis of hepatic disease. All subjects received sevoflurane, vecuronium, fentanyl, and cefuroxime in addition to dexmedetomidine during the study period; all but one also received tranexamic acid. The diagnoses or procedures for each group were as follows: Group intranasal DEX 1 mg kg À1 included two atrial septal defects, one ventricular septal defect, and three right ventricular outflow tract repairs (one pulmonary valvar stenosis and two truncus arteriosus). Group intranasal DEX 2 mg kg À1 included two atrial septal defects, two aortic stenosis variants (valvar aortic stenosis, sub-aortic stenosis), one partial atrioventricular canal defect, and one aortopexy for tracheal compression. Group i.v. DEX 1 mg kg À1 included one atrial septal defect, one tetralogy of Fallot, two atrioventricular canal variants, and two single ventricle variants with cavopulmonary anastomoses undergoing a modified Fontan procedure. No major adverse events (defined as administration of a vasopressor, chronotropic agent, or electrical pacing) occurred after dexmedetomidine administration until cannulation for CPB in any treatment group. 22 The duration of arterial blood sampling before CPB was at least 77 min in all patients (maximum 174 min).
Pharmacokinetic analysis
A total of 148 plasma samples were collected from 18 subjects. Plasma concentrations of dexmedetomidine over time for the three groups are presented in Table 2 and Fig 1. Individual plasma concentrations at different time points along with fitted PK profiles are shown in Supplementary Fig S1. The average peak measured dexmedetomidine concentration (C max ) was 199 (41) pg ml À1 at 46 (11) (Fig 2) .
The concentration time profile of i.v. and intranasally administered dexmedetomidine were best described with a two-compartment model, compared with a one compartment model (DOFV¼419). Application of a three-compartment model did not further improve the model fit. This two compartment model was parameterised with zero order infusion for i.v. and first order absorption for intranasal with lag time and incorporating bioavailability. The best fit was obtained by fixing the absorption rate constant (Ka) and lag time (ALAG) at 0.0157 min À1 and 5.00 min, respectively. Age analysed as estimated gestational age (EGA in weeks) was not found to be a significant covariate. 20 The final PK model captured the PK profiles well, as confirmed by the diagnostic plots (Fig 3) . Dexmedetomidine CL, V, and bioavailability were estimated by NONMEM. The population PK parameters along with estimated value and 95% CI for the i.v. and intranasal groups are summarised in Supplementary The typical bioavailability was estimated as 83.8% with a 95% CI of 69.5e98.1% and 8.72% RSE. The estimated CL, V1, Q, V2, bioavailability, Ka, and ALAG for each individual subject are listed in Supplementary Table S2 . The simulated PK profiles by VPC for both i.v. and intranasal administered dexmedetomidine (Fig 4) were in reasonable agreement with observed concentrations.
Discussion
Since the first description by Yuen and colleagues 24 in 2007, intranasal dexmedetomidine sedation is increasingly utilised for non-painful paediatric diagnostic procedures such as transthoracic echocardiography, computerised tomography, magnetic resonance imaging, and auditory brainstem response testing. 1 Dexmedetomidine is an attractive sedative because of its lack of respiratory depression, even at very high doses, 25 however, it can lead to hemodynamic compromise, emphasising the need for identifying the lowest dose to provide therapeutic effects. Although i.v. dexmedetomidine pharmacokinetics has been studied, no pharmacokinetic data of intranasal dexmedetomidine in children has previously The plasma concentrations observed after intranasal administration in our study were higher than plasma concentrations after oral and buccal administration, but lower than after i.m. and i.v. administration in adults. 23 The only other intranasal dexmedetomidine study was performed in adults by Iirola and colleagues. 14 In their study, intranasal dexmedetomidine was administered to six adult male volunteers by nasal spray device using a veterinary formulation of dexmedetomidine with a concentration of 500 mg ml À1 (0.2 ml).
Median peak arterial plasma concentration of 340 (range 230e700 pg ml À1 ) was reached within 38 min (range 15e60 min) and absolute bioavailability by non-compartmental analysis was 65% (range 35e93%). There was a large variation in time to peak concentration in both studies. The mean T max value in the current study (47 min) was longer than what has been reported for adults (38 min). 14 However, this difference was not statistically significant (P¼0.128). The target plasma concentration for paediatric procedural sedation using dexmedetomidine without concomitant opioids and benzodiazepines is unknown. The plasma concentration of dexmedetomidine to achieve sedation in adults may be approximately 200e400 pg ml À1 . 21, 23 Su and colleagues 26 reported minimal, moderate, and deep sedation with median plasma concentrations of 120, 370, and 430 pg ml À1 of dexmedetomidine in paediatric patients in the intensive care unit (ICU) with infusions of dexmedetomidine after cardiac surgery; however, these patients received supplemental midazolam and analgesics. Even higher plasma concentrations of 400e800 pg ml À1 have been reported for i.v. ICU sedation in children and adults. 27 Ebert and colleagues 25 reported that in adult volunteers, despite significant sedation, recall and picture recognition were preserved at plasma concentrations below approximately 1000 pg ml
À1
. From these studies, a dexmedetomidine therapeutic range for paediatric sedation with dexmedetomidine as a sole agent may be approximately 200e600 pg ml À1 . This concentration was reached in the group receiving 2 mg kg À1 intranasally (peak plasma concentration 333 pg ml
). Larger doses such as 3e4 mg kg À1 intranasal dexmedetomidine may produce plasma concentrations within this range and provide an earlier onset time, albeit with a higher potential for adverse hemodynamic effects. The haemodynamic effects of dexmedetomidine are biphasic depending on plasma concentration and speed of injection. 2 Plasma concentrations of dexmedetomidine greater than 1000 pg ml À1 can be associated with peripheral vasoconstriction and bradycardia. 13, 28 Initial hypertension with intranasal administration of dexmedetomidine in children has not been reported, although most studies have deferred blood pressure measurement before the onset of sedation. 7, 10 In the present study, no hypertension requiring treatment was observed by arterial pressure monitoring, albeit in anaesthetised patients. The relatively slow absorption and low maximum plasma concentration observed after nasal administration may explain why initial hypertension and bradycardia are not commonly reported with this route. Administration of intranasal dexmedetomidine has typically been reported in doses ranging from 1 to 3 mg kg À1 . 29, 30 Published pharmacodynamic data in young children sedated with intranasal dexmedetomidine from our institution and others show adequate sedation for non-painful procedures at approximately 20e30 min after administration, with duration of approximately 30e60 min. 7, 10, 29 We performed intranasal administration by atomisation, which has several potential advantages over simple nasal drop administration, such as uniform application throughout the nasal mucosa to maximise the area of absorption. However, a recent clinical study showed no difference between the two techniques with slow incremental administration of the nasal drops. The estimated bioavailability of intranasal dexmedetomidine in this study is similar to the bioavailability estimated in healthy adults (82.0%) as reported by Yoo and colleagues. 21 Other population PK parameters in the adult study were significantly lower than our results. In the adult study, both intranasal and i.v. doses were administered to a homogeneous population of healthy young males. In our study, separate patients received either intranasal or i.v. dose. Our patients were young children with congenital heart disease. Our sampling window was limited compared with the 10 h post-dose sample collection period in the adult study. All these factors might have contributed towards variation in the findings of the two studies.
The variability in observed pharmacodynamic effects of intranasal dexmedetomidine reported in other studies may be partially explained by the variation in intranasal absorption as noted in the present study in children and the previous study by Iirola and colleagues 14, 21 in adults. This suggests that there exists a continued need for an improved delivery system and optimised formulation for intranasal administration of dexmedetomidine. However, Vilo and colleagues 33 reported that even with i.v. dosing, marked inter-individual variation in pharmacokinetic parameters exists in young children. A more detailed study of covariates, including pharmacogenetics, may be required to attain a more personalised sedation protocol. 34 Intranasal administration of medications is thought to provide direct systemic absorption by bypassing hepatic firstpass metabolism, similar to buccal or sublingual administration. However, the nasal route may also produce effects by direct nose to brain delivery, potentially via the olfactory and trigeminal nerves, bypassing the bloodebrain barrier. 35 Extracellular transport is thought to occur within minutes of administration for some intranasal medications including peptides, such as insulin, and lipophilic drugs, such as cocaine. 18 We previously reported that intranasal dexmedetomidine produces sedation in a similar cohort of children with congenital heart disease within 26e28 min on average. 7, 10 Our current PK data (minimal lag time to absorption and peak plasma concentration in 47 min) suggests that a direct comparison of intranasal and buccal administration of dexmedetomidine with pharmacodynamic and plasma concentration measurements may be required to resolve whether a nose to brain component exists after intranasal administration. Our data contributes to the pharmacokinetic description of extravascular dexmedetomidine administration. With intranasal dexmedetomidine, we observed peak plasma concentrations exceeding those reported for buccal (5 min 'swish and spit') or orogastric administration (150 ml water) in adults (Fig  2) . 23 Peak plasma concentrations after buccal administration in adults occurred in 1.5 h on average and has not been studied in children. The buccal dexmedetomidine bioavailability determined by Anttila and colleagues 23 is confounded by correction for the 'amount of dexmedetomidine expelled from the mouth' after 5 min measured to be a mean of 44% of the administered dexmedetomidine. Thus, their published bioavailability for buccal administration of 82% is probably an overestimate in a practical paediatric sedation setting. Peak plasma concentrations after oral administration have been reported to average 2.2 h with a lag time of detectable plasma concentrations of 0.6 h and a bioavailability of 16%. Despite this, successful oral dexmedetomidine sedation with doses of approximately 5 mg kg À1 has been reported. 36 
Limitations
Our study was designed to characterise the absorption and peak plasma concentrations of dexmedetomidine after intranasal administration; however, in this clinical setting, the terminal elimination half-life could not be determined because of termination of sampling at the initiation of CPB which occurred approximately 2 h after the dexmedetomidine dose. This may have resulted in higher CL estimates. The metabolism and CL of i.v. dexmedetomidine has been well characterised in the postoperative ICU in patients after congenital cardiac surgery. 11, 37 Using our experimental model, we were unable to study i.v. and intranasal PK in the same patients and instead had to use different, though similar, individuals. Another limitation of our study was the administration to supine anaesthetised, tracheally intubated patients. Awake, spontaneously breathing patients sitting erect may achieve different results. While the volume of medication atomised was minimised, mucosal saturation and oropharyngeal runoff cannot be excluded. 38 Because of the complexity of cardiac surgical preparation, sternotomy, and cardiac dissection, we could not include haemodynamic data in this study. However, before surgical manipulation, no haemodynamic instability requiring treatment was observed. Future studies should also compare the pharmacokinetic profile of intranasal dexmedetomidine with simple nasal drop administration and by small volume buccal (or sublingual) administration in children. 31 We had one cyanotic patient in the 1 mg kg À1 intranasal dexmedetomidine group. Observed C max , T max , and estimated PK parameters in this cyanotic patient were 70e90% compared with values for non-cyanotic patient in the same dose group. However, no statistical conclusion can be drawn because of the small sample size. No significant difference was observed in estimated PK parameters of cyanotic and non-cyanotic patients in the 1 mg kg À1 i.v. dexmedetomidine group.
The population PK parameters in our study were scaled with body weight. There is a strong theoretical basis of using allometric scaling to account for the influence of body size on PK parameters. 20 Given the limited sample size, we did not evaluate which body size metric (body weight or body suface area (BSA)) would better correlate with PK parameters, but applied allometry theory. Future studies with more patients and in a younger age population are warranted to better understand the best body size metric associated with dexmedetomidine PK. We analysed EGA for covariate analysis and it was not found to be a significant covariate. However, the CL of most drugs reaches adult value by 1 yr of age 20 and we had very few patients younger than 1 yr. Future studies with younger patients will help understand the effect of maturation on dexmedetomidine PK.
Conclusions
Mean arterial plasma concentrations of dexmedetomidine in infants and toddlers approached 100 pg ml À1 , the low end reported for sedative efficacy, within 20 min of an atomised intranasal administration of 1 mg kg
À1
. Doubling the dose to 2 mg kg À1 reached this plasma concentration within 10 min and achieved almost twice the peak concentration. Peak plasma concentrations with both doses were reached within 47 min of intranasal administration, with an overall bioavailability of 84%. The concentration time profile was best described by a two-compartment model by population pharmacokinetic modelling.
